Compare ELTK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTK | ALXO |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.5M | 68.3M |
| IPO Year | 1997 | 2020 |
| Metric | ELTK | ALXO |
|---|---|---|
| Price | $9.20 | $2.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.42 |
| AVG Volume (30 Days) | 3.1K | ★ 579.5K |
| Earning Date | 03-10-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $49,310,000.00 | N/A |
| Revenue This Year | $18.60 | N/A |
| Revenue Next Year | $9.04 | N/A |
| P/E Ratio | $49.00 | ★ N/A |
| Revenue Growth | ★ 2.54 | N/A |
| 52 Week Low | $7.65 | $0.40 |
| 52 Week High | $12.19 | $2.41 |
| Indicator | ELTK | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 77.38 |
| Support Level | $8.55 | $1.36 |
| Resistance Level | $9.10 | $2.41 |
| Average True Range (ATR) | 0.47 | 0.23 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 81.47 | 95.92 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.